Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Shares Issued (2018 - 2025)

UroGen Pharma (URGN) has disclosed Shares Issued for 8 consecutive years, with $39.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued fell 73.63% year-over-year to $39.8 million, compared with a TTM value of $39.8 million through Dec 2025, down 73.67%, and an annual FY2025 reading of $39.8 million, down 73.67% over the prior year.
  • Shares Issued was $39.8 million for Q4 2025 at UroGen Pharma, up from -$324000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $150.9 million in Q4 2024 and bottomed at -$135.9 million in Q3 2024.
  • Average Shares Issued over 5 years is $15.1 million, with a median of $175500.0 recorded in 2021.
  • The sharpest move saw Shares Issued skyrocketed 37133.33% in 2022, then crashed 5035.98% in 2023.
  • Year by year, Shares Issued stood at $3000.0 in 2021, then surged by 12500.0% to $378000.0 in 2022, then plummeted by 5035.98% to -$18.7 million in 2023, then surged by 908.87% to $150.9 million in 2024, then plummeted by 73.63% to $39.8 million in 2025.
  • Business Quant data shows Shares Issued for URGN at $39.8 million in Q4 2025, -$324000.0 in Q3 2025, and $297000.0 in Q2 2025.